Icon Plc (NASDAQ:ICLR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Icon Plc (NASDAQ:ICLR) have been given an average recommendation of “Moderate Buy” by the twenty-two research firms that are covering the stock, Marketbeat.com reports. Twelve research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $203.8125.

A number of analysts have recently commented on the company. BMO Capital Markets started coverage on Icon in a research report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price target on the stock. Truist Financial reiterated a “hold” rating and set a $222.00 price objective (down previously from $231.00) on shares of Icon in a research note on Thursday. TD Cowen cut their target price on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Leerink Partners reaffirmed an “outperform” rating on shares of Icon in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th.

Icon Trading Down 3.6%

NASDAQ:ICLR opened at $181.38 on Monday. The firm has a market capitalization of $14.65 billion, a P/E ratio of 24.54, a PEG ratio of 3.82 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. Icon has a one year low of $125.10 and a one year high of $220.93. The company’s 50-day simple moving average is $177.26 and its 200 day simple moving average is $173.11.

Institutional Investors Weigh In On Icon

A number of institutional investors have recently made changes to their positions in ICLR. Private Trust Co. NA raised its holdings in Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares during the last quarter. Ameriflex Group Inc. purchased a new position in shares of Icon in the third quarter worth $33,000. Ameritas Advisory Services LLC bought a new position in shares of Icon during the second quarter valued at $48,000. LRI Investments LLC purchased a new stake in shares of Icon during the second quarter valued at $49,000. Finally, Blue Trust Inc. increased its holdings in Icon by 44.0% in the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after buying an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.